Birmingham, United Kingdom
PBD Biotech is a biotechnology company based in the United Kingdom that has developed Actiphage, a revolutionary blood test capable of detecting 'active', disease-causing tuberculosis infection. With approximately one quarter of the world’s population affected by latent tuberculosis (LTBI) and the risk of progression to active TB disease in around one in ten people with LTBI, there is a critical need for advanced diagnostic tests to predict the development of active disease among infected individuals.
Founded in 2014, PBD Biotech is dedicated to supporting the scale-up of latent tuberculosis test-and-treat campaigns through the utilization of Actiphage to help achieve the objectives of the WHO End TB strategy. The company aims to drive innovation in TB screening and drug management by leveraging Actiphage's unique role in detecting active TB.
The latest investment in PBD Biotech is a substantial £2.40M Venture Round investment received on 17 October 2022. This investment was made by the Midlands Engine Investment Fund and the University of Nottingham, signaling the company's potential and garnering support from prestigious institutional investors.
